Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,380.56 118.00 0.73%
S&P 500 1,857.70 14.72 0.80%
NASDAQ 4,072.26 38.10 0.94%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

SDIX Collaborates with Banyan Biomarkers in Work to Detect



  SDIX Collaborates with Banyan Biomarkers in Work to Detect Traumatic Brain
  Injury

Business Wire

NEWARK, Del. -- July 20, 2010

SDIX™ (Strategic Diagnostics Inc. d/b/a SDIX, NASDAQ: SDIX), today announced a
multi-year collaboration with Banyan Biomarkers, Inc. to provide products and
services for Banyan’s biomarker discovery work in the detection of traumatic
brain injury (TBI).

The partnership calls for SDIX to collaborate with Banyan on the development
of antibodies and immuno-solutions that include:

  * custom monoclonal and polyclonal antibody development
  * cell line banking and cryostorage
  * antibody production and purification – in vivo and in vitro

Dr. Walid Qoronfleh, SDIX Executive Director, Life Sciences, said, “We look
forward to working with Banyan Biomarkers as they continue their breakthrough
work addressing the unmet clinical needs for detecting TBI. We believe our
twenty years of experience in providing immuno-solutions; from antibody to
assay development, as well as our in vitro diagnostics expertise make SDIX a
valuable partner for companies like Banyan.”

Mr. Fran DiNuzzo, SDIX President and CEO said, “We appreciate the opportunity
to collaborate on this critical biomarker project with Banyan to help save and
improve the lives of patients with brain injuries, including the potential of
helping the brave men and women serving in our armed forces.”

“We look forward to working with SDIX on the development of antibodies and
immuno-solutions,” stated Jackson Streeter, MD, CEO of Banyan Biomarkers.
“This is an important step in the discovery of diagnostics and treatments for
TBI and other neurological disorders.”

According to the Centers for Disease Control (CDC), at least 1.7 million
suffer a traumatic brain injury (TBI) in the United States annually. That’s
more than the number diagnosed with the top five cancers combined according to
National Cancer Institute (NCI) statistics. Of those individuals, about 52,000
die, 275,000 are hospitalized, and 1.365 million are treated and released from
an emergency department. The International Brain Injury Association
(www.internationalbrain.org) reports 5.3 million Americans are living today
with disabilities related to TBI.

About Banyan Biomarkers (www.banyanbio.com)

Banyan Biomarkers is the leader in developing in vitro diagnostic products to
address unmet clinical needs for the detection of traumatic brain injury. The
Company is focused on developing a simple point-of-care blood test that will
be used by physicians to detect the presence and severity of brain trauma and
improve the medical management of head injured patients. Banyan Biomarkers has
a licensing agreement with the University of Florida for exclusive global use
of technology related to this product. To learn more visit
http://www.banyanbio.com.

About SDIX (www.sdix.com)

SDIX is a biotechnology company, expert at creating advantage by providing a
broad range of quality, innovative and effective immuno-solutions to the
pharmaceutical, biotechnology, diagnostics, and food safety markets. For
nearly 20 years, SDIX has developed antibodies and reagents which advance its
customers’ immuno-based work – reducing time, labor, and costs while
increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including
assay design, development, and production. In life science markets, SDIX
capabilities are being used to help discover the mechanisms of disease,
facilitate the development of new drugs, and provide mechanisms for rapid
diagnosis.

This news release may contain forward-looking statements reflecting SDIX's
current expectations. When used in this press release, words like
“anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”,
“potential”, “will”, “should”, “project”, “plan” and similar expressions as
they relate to SDIX are intended to identify said forward-looking statements.
Investors are cautioned that all forward-looking statements involve risks and
uncertainties, which may cause actual results to differ from those anticipated
by SDIX at this time. Such risks and uncertainties include, without
limitation, changes in demand for products, the application of our
technologies to various uses, delays in product development, delays in market
acceptance of new products, retention of customers and employees, adequate
supply of raw materials, inability to obtain or delays in obtaining fourth
party or required government approvals, the ability to meet increased market
demand, competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described in
SDIX's public filings with the U.S. Securities and Exchange Commission.

Contact:

SDIX
M. Walid Qoronfleh, PhD., MBA
302-456-6789
wqoronfleh@sdix.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement